ANALYTICA P E R I C O A C H
ANALYTICA LTD - ABN 12 006 464 866
ASX ANNOUNCEMENT
R&D Tax Incentive Receipt
18 January 2016: Analytica Ltd (ASX: ALT) is pleased to announce the receipt of $1,901k from the Australian Taxation Office under the Research and Development Incentive related to the financial year to 30th June 2015.The research and development tax incentive is an initiative of the federal government to assist small companies to invest in essential research and development to be internationally competitive with new innovative products. This incentive is a welcome boost to our research funding and Analytica is grateful for the support.
The continuing investment in the research and development of the PeriCoach® has led to a best in class, non- pharmaceutical, non-surgical treatment for pelvic floor muscle disorders, particularly stress urinary incontinence and sexual function. Pelvic floor muscles exercises are recommended by the American College of Physicians as a first line treatment for urinary incontinence.
The major focus of Analytica's research in 2015 is to demonstrate the efficacy of PeriCoach within a wide range of women suffering from urinary incontinence and other pelvic floor disorders. With every additional user further data is added to the only pelvic floor muscle database in the world. Internal data review and research shows improvement in pelvic floor muscles strength and tone. Clinical papers also document clinician's successful treatments and symptom improvements using the PeriCoach system. The most gratifying indicator of effectiveness are the testimonials and quality of life improvements that women share.
Further clinical evidence and health care economic data is being accumulated with an independent clinical trial underway.
Development continues on the PeriCoach to enhance the user's experience and to ensure a pipeline of features to keep the PeriCoach as the trusted solution for women and clinicians as well as expanding treatment opportunities.
CEO.
Analytica's lead product is the PeriCoach® System - an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.
PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.
PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The US market for incontinence pads is $5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence.
Analytica Limited issued this content on 2016-01-18 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-18 00:14:02 UTC
Original Document: http://www.analyticamedical.com/downloads/2016/20160118-ASX-ALT-RandDTaxIncentive.pdf
